Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc.

HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020

Third Quarter 2020 Financial Highlights

• Total revenues of $2.97 billion, a slight increase on an actual basis and a slight decrease on a constant currency basis, compared to the prior year period.
• Revenue Highlights:
• North America segment net sales of $1.03 billion, down 5% on an actual and constant currency basis.
• Europe segment net sales of $1.12 billion, up 7%, up 2% on a constant currency basis.
• Rest of World segment net sales of $795.5 million, up less than 1%, up 3% on a constant currency basis.
• U.S. GAAP net earnings of $185.7 million, compared to U.S. GAAP net earnings of $189.8 million in the prior year period.
• Adjusted net earnings of $679.7 million, compared to adjusted net earnings of $604.4 million in the prior year period.
• Adjusted EBITDA of $1.01 billion, compared to adjusted EBITDA of $922.8 million in the prior year period.

Nine Months Ended September 30, 2020 Financial Highlights

• Total revenues of $8.32 billion, a slight increase on an actual basis, up 1% on a constant currency basis, compared to the prior year period.
• Revenue Highlights:
• North America segment net sales of $3.02 billion, essentially flat on an actual and constant currency basis.
• Europe segment net sales of $3.08 billion, up 5% on an actual and constant currency basis.
• Rest of World segment net sales of $2.13 billion, down 5%, down 1% on a constant currency basis.
• U.S. GAAP net earnings of $245.9 million, compared to U.S. GAAP net loss of $3.7 million in the prior year period.
• Adjusted net earnings of $1.72 billion, compared to adjusted net earnings of $1.56 billion in the prior year period.
• Adjusted EBITDA of $2.64 billion, compared to adjusted EBITDA of $2.48 billion in the prior year period.
• U.S. GAAP net cash provided by operating activities for the nine months ended September 30, 2020 of $1.20 billion, compared to net cash provided by operating activities of $1.12 billion in the prior year period, and adjusted free cash flow for the nine months ended September 30, 2020 of $1.51 billion, compared to $1.29 billion in the prior year period.

Mylan is not providing forward-looking information for U.S. GAAP reported financial measures or a quantitative reconciliation of forward-looking non-GAAP financial information. Please see "Non-GAAP Financial Measures" for additional information.

Mylan Chief Executive Officer Heather Bresch commented: "As we prepare to officially conclude the Mylan story and provide what will be the company's final earnings update, Mylan's strong year-to-date results once again demonstrate the benefits of the diverse and durable platform that we have created. I'm extremely proud of how Mylan has performed over the last nine months during these unprecedented times. I sincerely thank our 35,000 employees across the globe for their consistent performance and dedication to providing access to medicine to patients around the world, even while navigating the realities of a global pandemic. It is this unwavering commitment to our mission that has served the company well for almost 60 years, and I am confident will pave the way for the success of Viatris in the years to come."

Mylan Executive Chairman Robert J. Coury commented: "On behalf of Mylan's Board of Directors and all Mylan employees, I would like to thank Heather for her truly exemplary leadership and lasting contributions to the company, the industry and patients around the world. As we officially close the book on Mylan, I would also like to offer my sincere appreciation and gratitude to all the Mylan employees, both past and present, for their extraordinary resilience and determination to help us reach this pivotal moment in our 60-year history. 

"With just 10 days until we close our proposed combination with Pfizer's Upjohn business, we are excited to bring the two organizations together.  Starting on Day 1, management's full attention will now be turned towards executing upon the integration plan and developing Viatris' operating strategy. We intend to provide details on Viatris' strategy, including 2021 guidance, at our upcoming Investor Day, to be held in late February or early March 2021.